TCOV
CAI

Trust Company of Vermont’s Caris Life Sciences CAI Stock Holding History

Trust Company of Vermont’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$8.9K Buy
+330
New +$9.29K ﹤0.01% 864

Other funds holding CAI

JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $326M AUM
SSP
Sixth Street Partners Dallas, Texas $711M AUM 9.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Trust Company of Vermont's CAI Position: Q4 2025 in Review

Trust Company of Vermont opened a new position in Caris Life Sciences (CAI) in Q4 2025: 330 shares worth $8.9K. The stake represents ﹤0.01% of the portfolio and ranks #864 among its holdings.

186 funds tracked by Wall St. Rank hold CAI as of Q4 2025.

  • Trust Company of Vermont held 330 shares of Caris Life Sciences worth $8.9K as of Q4 2025.
  • Caris Life Sciences was a new Trust Company of Vermont position in Q4 2025.
  • Caris Life Sciences made up ﹤0.01% of Trust Company of Vermont's portfolio in Q4 2025, its #864 holding.
  • 186 funds tracked by Wall St. Rank held Caris Life Sciences as of Q4 2025.

Based on Trust Company of Vermont's 13F filing for Q4 2025, filed 16 Jan 2026.